Phase 2 Study to Investigate the Efficacy, Safety, and Tolerability of Six Weeks Treatment With V565 in Subjects With Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs V 565 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms HarbOR
- 07 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018.
- 13 Jan 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2016 New trial record